NYSE:LCI - New York Stock Exchange, Inc. - US5160122009 - Common Stock - Currency: USD
NYSE:LCI (4/19/2023, 8:06:04 PM)
0.6855
+0.03 (+3.86%)
The current stock price of LCI is 0.6855 USD. In the past month the price decreased by -59.68%. In the past year, price decreased by -74.42%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 71.52 | 882.60B | ||
JNJ | JOHNSON & JOHNSON | 16.74 | 402.75B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 28.02 | 396.72B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 21.02 | 236.00B | ||
MRK | MERCK & CO. INC. | 12.19 | 235.64B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.93 | 218.48B | ||
PFE | PFIZER INC | 8.44 | 148.76B | ||
SNY | SANOFI-ADR | 14.17 | 141.71B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 52.52 | 121.43B | ||
GSK | GSK PLC-SPON ADR | 8.09 | 77.44B | ||
ZTS | ZOETIS INC | 28.81 | 76.94B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 33.73 | 47.05B |
Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. The company is headquartered in Trevose, Pennsylvania and currently employs 564 full-time employees. The company went IPO on 2002-04-15. The firm markets approximately 100 products, mainly tablet, capsule or liquid oral generic medications. Its marketed products include generics such as Posaconazole, Fluphenazine, Levothyroxine, Sumatriptan and NDA-based product Numbrino. The Company’s product portfolio include Amphetamine IR Tablets, which are used to treat Attention deficit hyperactivity disorder (ADHD) and narcolepsy; Dicyclomine tablets, used for the treatment of functional bowel disorder and irritable bowel syndrome; Levothyroxine Capsules, used to treat patients with hypothyroidism and other conditions, and Numbrino Nasal Solution, used for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults, among others.
LANNETT CO INC
1150 Northbrook Drive, Suite 155
Trevose PENNSYLVANIA 19136 US
CEO: Timothy C. Crew
Employees: 564
Company Website: https://www.lannett.com/
Phone: 12153339000.0
The current stock price of LCI is 0.6855 USD. The price increased by 3.86% in the last trading session.
The exchange symbol of LANNETT CO INC is LCI and it is listed on the New York Stock Exchange, Inc. exchange.
LCI stock is listed on the New York Stock Exchange, Inc. exchange.
9 analysts have analysed LCI and the average price target is 4.08 USD. This implies a price increase of 495.19% is expected in the next year compared to the current price of 0.6855. Check the LANNETT CO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LANNETT CO INC (LCI) has a market capitalization of 7.38M USD. This makes LCI a Nano Cap stock.
LANNETT CO INC (LCI) currently has 564 employees.
The Revenue of LANNETT CO INC (LCI) is expected to decline by -11.78% in the next year. Check the estimates tab for more information on the LCI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LCI does not pay a dividend.
LANNETT CO INC (LCI) will report earnings on 2023-05-02, after the market close.
LANNETT CO INC (LCI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.44).
ChartMill assigns a fundamental rating of 1 / 10 to LCI. LCI may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months LCI reported a non-GAAP Earnings per Share(EPS) of -6.44. The EPS decreased by -129.18% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 47% to LCI. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -3.01% and a revenue growth -11.78% for LCI